Generics Gateway

If generics are the gateway of growth for global pharmaceutical giants such as AstraZeneca, Pfizer, Sanofi-Aventis, Novartis, Merck and GlaxoSmithKline, there is a clear and renewed thrust on the $17 billion Indian pharmaceutical market.

Recovery pangs

Banking, financial services and insurance industry has always been a harbinger of things to come for tech majors. The largest outsourcer to the $50 billion software services industry, BFSI was the first casualty of the global economic crisis. This vertical is the also the first to bounce back and show a recovery.

Healthy demand

The PC monitor market in Asia/Pacific excluding Japan region totaled 29.5 million units in 1H09, representing an increase of 4.8% over 1H08, and 7.6% over 2H08

Data Crunching Made Easy

Uncovering new ways to treat diseases from increasing biological data remains a daunting task for a life sciences researcher. With new drugs taking years of resource-intensive research, development, testing and marketing, researchers at pharmaceutical and biotech companies must ensure that processes are completed as quickly, accurately, and inexpensively as possible.

Telecom Scramble

Telecom industry is getting ready for a makeover this festive season. New operators have entered the already crowded telecom space, seeking a slice of the market pie where Bharti and Reliance dominate the GSM and CDMA space respectively.

Vaccines are hot

The race to offer H1N1 flu vaccination is picking up pace. While global H1N1 vaccine manufacturers like Sanofi Pasteur, Novartis and MedImmune have begun shipping their products, Indian vaccine majors Serum Institute of India, Panacea Biotech and Bharat Biotech are likely to start human clinical trials by the year-end and the H1N1 vaccine will hit the market by March-April next year.

One more total solutions play?

The interesting facet of the latest megadeal announced in the global IT industry is not the rationale for what is clearly an attempt by the last pure play hardware provider to become a true solutions provider, but the strategy that will be deployed to ensure that this acquisition justifies the high ticket price that has been paid to do the deal.

Ripple Effect

Just six months back, doing away with Perot Systems was probably not even on the mind of company’s consulting practice chairman, Jim Champy. During a very short chat on his way to the Mumbai International Airport, Champy seemed excited about the healthcare sector.

Ringing in 3G

Buzz around third generation mobile communications is getting stronger in India. After months of dithering, the government agencies have finally managed to clear the mist encircling the 3G auctions.

Fake Syndrome

Are you worried about the safety of your medicines? You have every reason to be. Chances are the most frequently prescribed medicines such as painkillers, cough medicines, antibiotics or anti-inflammatory tablets that you pick up from the neighbourhood chemist are counterfeit.

New kids on the computing block

When Nokia and Sony log into the nascent netbook market, the computing world is bound to take notice. While the world’s largest mobile phone maker is touting a feature packed bundle of connectivity, consumer electronics giant Sony is promising to add a touch of style.

A bitter pill to swallow

Global pharmaceutical majors are not getting healthy indicators from the $8 billion domestic pharmaceutical market, especially on the intellectual property and data protection front.

Visa clamps

Tech and outsourcing majors are getting ready for a surprise visitor at their American offices—US Citizenship & Immigration Services. The agency that administers the H-1B and L-1 visa programmes has started making surprise audits of the US workplaces of companies that sponsor H-1B and L-1 visa holders.

Biotech copies get a red flag

Indian biotech industry’s much-cherished dream of launching generic biotech drugs in the US market seems to be going sour. High-level policy changes in the US political establishment seem to be favouring protection for biotech drugs from competition from cheaper generic rivals for 12 years.

Homeward bound

You could call it the return of the prodigal. After shying away from the domestic IT market for long, Indian IT majors are slugging it out with global tech bigwigs for a piece of the Indian technology pie.

The French connection

Indian vaccine makers seem to have entered good times. As France’s largest drug maker, Sanofi-Aventis, agrees to buy a majority stake in Hyderabad-based Shantha Biotechnics, a sense of excitement combined with renewed confidence has rejuvenated the domestic vaccine makers.

Cloning Glory

India is fast logging into the clone age. Despite being a late entrant into the elite group of nations such as the US, United Kingdom, South Korea and China, which are at the forefront of animal cloning efforts, India has recently achieved significant successes.

Tax Reboot

Pranab Mukherjee’s Budget 2009-10 might have been largely branded as a conservative affair, but not for the $50 billion Indian software exports industry.

SMB IT's newest interest

It's a three-letter word that vendors love using these days. SMB, short for small and medium businesses, are a hot topic of discussion in IT circles. There is a reason for it. Part of it incidentally is linked to the slowdown that the industry is witnessing at the moment.

New age services to citizens

In the recent Shanghai Cooperation Organisation Summit, the Prime Minister expressed his desire to intensify reforms and development in the areas of energy, security, infrastructure development, agriculture, transportation, science and technology and education.

Big opportunity to promote Web

Internet is a critical technology. While India is experiencing high growth and expectations, we are far behind Brazil and China with respect to internet access and usage.

Latest News

Print Edition

Events